Items Tagged ‘ENESTnd trial’

April 7, 2015

Tasigna® Remains Superior to Gleevec® for Treatment of Newly Diagnosed Patients With Chronic Myeloid Leukemia


Tasigna® (nilotinib) remains superior to Gleevec® (imatinib) for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (PH+CML), according to the results of the six-year update from the ENESTnd trial which were presented at the 56th annual meeting of the American Society of Hematology (ASH) in San Francisco.  These data are consistent with that […]

View full entry

Tags: Chronic Myeloid Leukemia, CML, ENESTnd trial, Gleevec, imatinib, Leukemia, News, nilotinib, Philadelphia chromosome positive, Tasigna